Cigna (CI) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Cigna (CI) reported $65.45 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 14.3%. EPS of $6.74 for the same period compares to $6.47 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $60.8 billion, representing a surprise of +7.66%. The company delivered an EPS surprise of +5.48%, with the consensus EPS estimate being $6.39.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Cigna performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Medical Care Ratio - Cigna Healthcare: 82.2% versus 82.4% estimated by seven analysts on average. Medical Customers - Total: 18.04 million versus 18.33 million estimated by four analysts on average. Healthcare Medical Customers - Insured - U.S. Healthcare: 2.65 million compared to the 3.23 million average estimate based on two analysts. Covered Lives By Funding Type - Medical Customers - International Health insured: 1.23 million compared to the 1.23 million average estimate based on two analysts. Revenues- Pharmacy: $48.63 billion compared to the $45.58 billion average estimate based on five analysts. The reported number represents a change of +15.7% year over year. Revenues- Net investment income: $238 million compared to the $255.45 million average estimate based on five analysts. The reported number represents a change of -17.9% year over year. Revenues- Evernorth Health Services: $53.68 billion versus $50.54 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +16.1% change. Revenues- Cigna Healthcare: $14.53 billion compared to the $12.16 billion average estimate based on five analysts. The reported number represents a change of +9.4% year over year. Revenues- Cigna Healthcare- Premiums: $12.63 billion versus $11.02 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +9.5% change. Revenues- Evernorth Health Services- Pharmacy: $50.23 billion compared to the $47.34 billion average estimate based on five analysts. The reported number represents a change of +16.3% year over year. Revenues- Fees and Other: $3.90 billion versus $3.84 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +17.1% change. Revenues- Premiums: $12.74 billion versus $10.60 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +9.8% change. View all Key Company Metrics for Cigna here>>>Shares of Cigna have returned -1% over the past month versus the Zacks S&P 500 composite's -0.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cigna Group (CI): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks